- Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a

LEXINGTON, Mass., Aug. 2, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on Thursday,

-- Sunil Gupta, MD, named Vice President Regulatory & Pharmacovigilance -- Anna Wijatyk, MD, named Vice President Clinical Development LEXINGTON, Mass., July 16, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of

LEXINGTON, Mass., June 20, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1  invites investors and the general public to attend its Annual Meeting of Stockholders to begin

-- Novel discovery improves the immunological activity of certain cancer fighting antibodies -- Agenus' next generation anti-CTLA-4 antibody (AGEN1181) developed using this technology is slated for IND in 2018 LEXINGTON, Mass., June 12, 2018 / PRNewswire / -- A study published in Cancer Cell

LEXINGTON, Mass., June 6 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer

- AGEN1884 and AGEN2034 produce clinical benefit 2  in 31% and 42% of patients respectively - Combination trial of AGEN1884 plus AGEN2034 in 2L cervical cancer ongoing to support BLA LEXINGTON, Mass., June 4 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a

- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses - More than 100 patients treated with AGEN1884 and AGEN2034 - Combination trial has commenced in cervical cancer LEXINGTON, Mass., May 17 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a

Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and

LEXINGTON, Mass., May 7 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Garo Armen, Ph.D., Chairman & CEO, and Jennifer Buell, Ph.D., Chief

LEXINGTON, Mass., May 3, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday, May 07,

LEXINGTON, Mass., May 1, 2018 / PRNewswire / -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz, Vice President, Head of

LEXINGTON, Mass., April 11 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three abstracts were accepted for presentation at the AACR 2018 Annual Meeting in Chicago from April

LEXINGTON, Mass., March 29, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare

LEXINGTON, Mass. , March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for fourth quarter and full year 2017.

LEXINGTON, Mass., March 7, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, March 15, 2018.

- Combination trial accrual completed in first cohort of patients - Commercial grade AGEN1884 and AGEN2034 to be available by mid-year - Non-exclusive access to partners for clinical and commercial supplies LEXINGTON, Mass., Jan. 22, 2018 / PRNewswire / -- Agenus Inc.

LEXINGTON, Mass., Jan. 22, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).

LEXINGTON, Mass., Jan. 8, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).

LEXINGTON, Mass., Jan. 4, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle, Head of Translational Medicine and Bioinformatics ,  will participate in a panel

-- Hagop Youssoufian, MD, named Senior Clinical Strategist -- John Castle, Ph.D., appointed as Head of Translational Medicine and Bioinformatics -- Tyler Curiel, MD, MPH named Senior Strategist for Translational and Biomarker Development LEXINGTON, Mass., Jan. 3, 2018 / PRNewswire / -- Agenus Inc.

LEXINGTON, Mass., Nov. 15, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license

- Plans to file first BLA 2H2019 - Combination trials in 1L NSCLC, monotherapy trials in 2L cervical cancer and cutaneous squamous cell carcinoma advancing - Data presented at SITC on pharmacologic activity of AGEN CTLA-4 and PD-1 antibodies - GMP clinical grade supply available for Agenus and

LEXINGTON, Mass., Nov. 8, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, and Michael Plater,

Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results